CD274 and non-small cell lung carcinoma: In a meta-analysis comparing PD-1 and PD-L1 monoclonal antibodies in terms of efficacy and toxicity in NSCLC, there was no difference in response rates (19% and 18.6%) and the overall incidence of adverse events (64% and 66%) between both classes of agents [103].